VEGF — Vascular Endothelial Growth Factor & PDRN

Vascular Endothelial Growth Factor (VEGF) is a homodimeric glycoprotein and the most potent known inducer of angiogenesis — the formation of new blood vessels from pre-existing vasculature. First isolated and characterized by Napoleone Ferrara in 1989, VEGF acts as a highly specific mitogen for vascular endothelial cells and plays a central role in both physiological and pathological neovascularization .

Definition

VEGF refers to a family of structurally related proteins, of which VEGF-A is the most extensively studied and biologically significant member. The VEGF family also includes VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF). VEGF-A exists in multiple splice variants (VEGF121, VEGF165, VEGF189, VEGF206), with VEGF165 being the predominant isoform in most tissues . These proteins signal primarily through two receptor tyrosine kinases: VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1), with VEGFR-2 mediating the major angiogenic responses.

Biological Functions

Angiogenesis and Vasculogenesis

VEGF is the master regulator of blood vessel formation. It promotes angiogenesis through several coordinated actions :

Endothelial cell proliferation — VEGF stimulates division of endothelial cells lining blood vessels
Endothelial cell migration — VEGF gradients direct endothelial cells toward hypoxic or damaged tissue
Vascular permeability — VEGF increases permeability of existing vessels, allowing plasma proteins to extravasate and form a provisional matrix for migrating cells
Endothelial cell survival — VEGF provides anti-apoptotic signals that protect newly formed endothelial cells

Regulation by Hypoxia

VEGF expression is powerfully induced by hypoxia (low oxygen tension) through the transcription factor HIF-1alpha (hypoxia-inducible factor 1-alpha). When tissue oxygen levels drop — as occurs in wounds, ischemic tissue, or rapidly growing tissue — HIF-1alpha stabilizes and drives transcription of the VEGF gene . This hypoxia-VEGF axis ensures that tissues in metabolic need receive new vascular supply.

Role in Wound Healing

VEGF is essential for normal wound healing. During the proliferative phase of wound repair, VEGF produced by fibroblasts, keratinocytes, macrophages, and endothelial cells drives the formation of granulation tissue — the highly vascularized tissue that fills wound defects . Without adequate VEGF signaling, wound healing is impaired, as seen in chronic wounds associated with diabetes and vascular disease.

PDRN Connection

PDRN (polydeoxyribonucleotide) has been demonstrated to significantly upregulate VEGF expression in both in vitro and in vivo models. This VEGF-stimulating effect is one of the primary mechanisms through which PDRN promotes tissue regeneration .

Mechanism of VEGF Upregulation

PDRN activates the adenosine A2A receptor on cell surfaces, triggering intracellular cAMP/PKA signaling cascades that enhance VEGF gene transcription. In the landmark study by Galeano et al., PDRN treatment in genetically diabetic mice — a model of impaired wound healing — produced significant increases in VEGF expression within wound tissue. This led to enhanced angiogenesis, improved granulation tissue formation, and accelerated wound closure .

Downstream Effects

The PDRN-induced increase in VEGF leads to a cascade of regenerative events:

Enhanced angiogenesis — New capillaries form, improving oxygen and nutrient delivery to healing tissue
Improved fibroblast function — Better vascularization supports fibroblast proliferation and collagen deposition
Accelerated wound closure — The combined angiogenic and proliferative effects speed overall tissue repair
Reduced ischemic damage — In compromised tissues (e.g., diabetic skin), VEGF-driven neovascularization restores perfusion

Clinical Significance

Regenerative Dermatology

VEGF upregulation by PDRN is directly relevant to clinical outcomes in regenerative skincare. PDRN-based products such as Rejuran Healer leverage this mechanism to improve skin quality, accelerate healing after procedures, and restore vascularity to aging or damaged skin .

Chronic and Diabetic Wounds

Impaired VEGF signaling is a hallmark of chronic non-healing wounds, particularly in diabetic patients. PDRN's ability to restore VEGF expression in these contexts has demonstrated therapeutic potential, with studies showing improved healing rates in diabetic wound models .

Anti-Aging Applications

Age-related decline in dermal vascularity is partly driven by reduced VEGF production. By stimulating VEGF expression, PDRN helps counteract this vascular decline, supporting the nutrient delivery and oxygenation that maintain skin thickness, elasticity, and overall health.

Angiogenesis — The process directly regulated by VEGF
Polydeoxyribonucleotide — PDRN's mechanism including VEGF upregulation
Wound Healing — The clinical context where VEGF is most critical
Fibroblast — Key cell type that benefits from VEGF-driven angiogenesis
Growth Factors — The broader family of signaling molecules that includes VEGF